Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Receivables - Other: 2021

  • Foghorn Therapeutics' Receivables - Other was N/A to $300.0 million in Q4 2021 from the same period last year, while for Dec 2021 it was $300.0 million, marking a year-over-year change of. This contributed to the annual value of $300.0 million for FY2021, which is N/A change from last year.
  • As of Q4 2021, Foghorn Therapeutics' Receivables - Other stood at $300.0 million.
  • In the past 5 years, Foghorn Therapeutics' Receivables - Other registered a high of $300.0 million during Q4 2021, and its lowest value of $300.0 million during Q4 2021.
  • Over the past 1 years, Foghorn Therapeutics' median Receivables - Other value was $300.0 million (recorded in 2021), while the average stood at $300.0 million.